Pulmonx Corporation (LUNG) Tops Q4 EPS by 12c

Pulmonx Corporation (NASDAQ: LUNG) reported Q4 EPS of ($0.33), $0.12 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $23.8 million versus the consensus estimate of $22.29 million.

For earnings history and earnings-related data on Pulmonx Corporation (LUNG) click here.

You May Also Be Interested In

• Bloom Energy rejects short-seller report on finances and supply chain
• Scienture to ship naloxone nasal spray to wholesalers in July
• ZeroStack secures up to $14.7M in pharmaceutical purchase orders